Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B, 02591) released its monthly return for the period ended 28 February 2026, confirming no change in its issued share capital composition. The total authorised share capital amounted to RMB 456.82 million, comprising 420.29 million H shares listed on the Stock Exchange and 36.53 million unlisted shares.

As of the end of February 2026, the number of issued H shares remained at 420.29 million, and the public float requirement of 25.00% was fulfilled. The unlisted shares continued at 36.53 million. There were no outstanding share options, warrants, or convertible securities during the reporting period, and the company had no treasury shares on record.

The return was submitted on 4 March 2026 by the Joint Company Secretary, stating that all disclosure and regulatory obligations had been met.